Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
World game at war: why some European nations have threatened a World Cup boycott 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
SEATTLE, May 08, 2018 -- Atossa Genetics Inc. (NASDAQ:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has received notice from NASDAQ that Atossa has regained compliance with NASDAQ minimum closing bid price listing rule 5550(a)(2). Atossa has received notice from NASDAQ stating, in part, that the "Staff has determined that for the last 10 consecutive business days, from April 20 to May 3, the closing bid price of the Company's common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and this matter is now closed."
About Atossa Genetics
Atossa Genetics Inc. is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com.
Forward-Looking Statements
Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with any variation between preliminary and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others with respect to fulvestrant, such as patent rights, potential market sizes for Atossa’s drugs under development and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.
Atossa Genetics Company Contact:
Atossa Genetics Inc.
Kyle Guse
CFO and General Counsel
Office: 866 893-4927
[email protected]
Investor Relations Contact:
Scott Gordon
CoreIR
377 Oak Street
Concourse 2
Garden City, NY 11530
Office: 516 222-2560
[email protected]
Source: Atossa Genetics Inc.
